ß-catenin signaling inhibitors ICG-001 and C-82 improve fibrosis in preclinical models of endometriosis.
Sci Rep
; 9(1): 20056, 2019 12 27.
Article
em En
| MEDLINE
| ID: mdl-31882904
ABSTRACT
Endometriosis exhibits unique characteristics, such as fibrosis, resistance to apoptosis, and promotion of cell proliferation; however, its pathophysiology is not fully understood. Recurrence rates after treatment are high, and the progression risk continues until menopause; hence, more effective therapy for endometriosis is needed. CREB-binding protein (CBP)/ß-catenin signaling inhibitors have demonstrated antifibrogenetic effects in liver, lung, and skin diseases. The present study evaluated the effects of two CBP/ß-catenin signaling inhibitors, ICG-001 and C-82, on the progression of endometriosis using endometriotic cyst stromal cells from the ovary and normal endometrial stromal cells from the uterus. ICG-001 was also evaluated in a mouse model. ICG-001 and C-82 inhibited cell proliferation, fibrogenesis, and cell migration, and promoted apoptosis in vitro. ICG-001 inhibited the growth of endometriotic lesions in the mouse model. CBP/ß-catenin signaling plays an important role in the pathophysiology of endometriosis. Inhibiting the CBP/ß-catenin signal can be a therapeutic target for endometriosis.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Pirimidinonas
/
Transdução de Sinais
/
Compostos Bicíclicos Heterocíclicos com Pontes
/
Endometriose
/
Beta Catenina
/
Compostos Heterocíclicos com 2 Anéis
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article